A5023342846- Platelet Disorders and Treatments
- Blood groups and transfusion
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Hemophilia Treatment and Research
- Autoimmune Bullous Skin Diseases
- Multiple Myeloma Research and Treatments
- Cell Adhesion Molecules Research
- Renal Diseases and Glomerulopathies
- Acute Myeloid Leukemia Research
- Blood properties and coagulation
- Immunotherapy and Immune Responses
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hematopoietic Stem Cell Transplantation
- Immunodeficiency and Autoimmune Disorders
- Kruppel-like factors research
- Retinoids in leukemia and cellular processes
- NF-κB Signaling Pathways
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Mesenchymal stem cell research
- Blood Coagulation and Thrombosis Mechanisms
- Lymphoma Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
Henan Cancer Hospital
2016-2025
Zhengzhou University
2016-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2011-2024
Kunming Medical University
2022-2024
Peking Union Medical College Hospital
2024
First People's Hospital of Yunnan Province
2022-2023
First Affiliated Hospital of Zhengzhou University
2016
Institute of Hematology & Blood Diseases Hospital
2011-2012
Guangdong Medical College
2012
Xuzhou Medical College
2001-2005
Abstract Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks adults with immune thrombocytopenia (ITP). This III study aimed evaluate the efficacy safety of hetrombopag ITP patients. Methods Patients who had not responded or relapsed after previous treatment were treated an initial dosage once-daily 2.5 5 mg (defined as HETROM-2.5 HETROM-5 group) matching placebo randomized, double-blind,...
Background: Polycythemia vera (PV) is a myeloproliferative neoplasm. Ropeginterferon alfa-2b new-generation polyethylene glycol-conjugated proline-interferon. It approved for the treatment of PV at starting dose 100 µg (50 patients receiving hydroxyurea (HU)) and titrations up to 500 by 50 increments. The study was aimed assessing its efficacy safety higher simpler intra-patient escalation. Methods: Forty-nine with having HU intolerance from major hospitals in China were treated biweekly an...
Although ruxolitinib improves splenomegaly and constitutional symptoms in patients with myelofibrosis (MF), a substantial proportion of discontinue because intolerance. This phase 2 trial investigated the safety efficacy jaktinib, novel JAK inhibitor ruxolitinib-intolerant MF. The primary endpoint was ≥35% reduction spleen volume (SVR35) at week 24. secondary endpoints included change MF-related symptoms, anemic response, profiles. Between December 18, 2019, November 24, 2021, 51 were...
Sequential combination bypass therapy (SCBT) is an effective treatment option for haemophilia patients with inhibitors; however, its safety, efficacy, and cost have largely yet to be systematically evaluated. To address this question, we retrospectively analyzed the medical records of 14 high titer inhibitors who underwent surgery. The were treated two SCBT regimens by optimizing doses recombinant activated factor VII (rFVIIa) prothrombin complex concentrate (PCC). effectiveness safety In...
<title>Abstract</title> Building on promising phase 1 pilot results demonstrating safety and efficacy of BBM-H901 (AAV-mediated FIX Padua gene therapy) in restoring factor IX activity (FIX:C) among 10 patients with haemophilia B, we conducted current studies to verify its larger Chinese B patients. A multicentre, single-arm, open-label study (phase 1/2: dose-escalation, n = 6; 3: fixed-dose, 26) a long- term study(n 10) were conducted. Eligible participants received 5×10¹² vg/kg...
Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown etiology. The underlying pathophysiological mechanism of moyamoya remains to be elucidated, but recent studies have increasingly highlighted that abnormal immune response may potential trigger for MMD. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), and systemic immune-inflammation index (SII) are inflammatory markers can reflect the state disease.The purpose this study was investigate SII, NLR, PLR in...
Background Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in patients with chronic or resolved HBV undergoing anticancer therapy. There risk reactivation after infusion chimeric antigen receptor (CAR) T cells for refractory/relapsed (R/R) multiple myeloma (MM). Methods We administered cell maturation (BCMA) CAR-T by to nine R/R MM infection. Patient serum was analyzed determine the expression five components and copy number DNA. defined if patient...
Abstract Acquired hemophilia A (AHA) is a rare but serious bleeding disorder. Randomized controlled trial (RCT) comparing the efficacy of immunosuppression therapy for AHA lacks. We conducted first multicenter RCT aiming to establish whether single‐dose rituximab combination regimen was noninferior cyclophosphamide regimen. From 2017 2022, 63 patients with newly diagnosed from five centers were randomly assigned 1:1 receive glucocorticoid (methylprednisolone 0.8 mg/kg per day 3 weeks and...
While studies have explored the feasibility of switching between various thrombopoietin receptor agonists in treating immune thrombocytopenia (ITP), data on from eltrombopag to hetrombopag remains scarce. This post-hoc analysis a phase III trial aimed assess outcomes ITP patients who switched hetrombopag. In original trial, initially randomized placebo group were eltrombopag. Those completed this 14-week eligible switch 24-week Treatment response, defined as platelet count ≥ 50 × 10
Rare but critical bleeding events in primary immune thrombocytopenia (ITP) present life-threatening complications patients with ITP, which severely affect their prognosis, quality of life, and treatment decisions. Although several studies have investigated the risk factors related to large sample size data, consistent definitions, large-scale multicenter findings, prediction models for ITP are unavailable. For first time, this study, we applied newly proposed criteria by International...
Bleeding episodes in hemophiliacs with inhibitors are difficult to control. Staidson protein-0601 (STSP-0601), a specific factor (F)X activator purified from the venom of Daboia russelii siamensis, has been developed.We aimed investigate efficacy and safety STSP-0601 preclinical clinical studies.In vitro vivo studies were performed. A phase 1, first-in-human, multicenter, open-label trial was conducted. The study divided into parts B. Hemophiliacs eligible for this study. Patients received...
Ruxolitinib has demonstrated efficacy in patients with myelofibrosis (MF). However, substantial number of may not respond after 3-6 months treatment or develop resistance over time. In this phase 2 trial, a current diagnosis intermediate high-risk MF who either had an inadequate splenic response spleen regrowth ruxolitinib were enrolled. All received jaktinib 100 mg Bid. The primary endpoint was the proportion ≥35% reduction volume (SVR 35) at week 24. secondary endpoints included change...
The development of inhibitors against factor FIX (FIX) is the most serious complication replacement therapy in haemophilia B (HB) patients. Currently, only few cohorts HB inhibitor patients have been reported worldwide.This Chinese nationwide study explored their risk factors for and experience on management.We retrospectively analysed patient characteristics, F9 genotypes, treatment strategies outcomes registered to National Registry Patient Organization Registry.Forty-four unique were...